MedPath

RAPT Therapeutics

RAPT Therapeutics logo
🇺🇸United States
Ownership
Public
Established
2015-03-04
Employees
131
Market Cap
$80.9M
Website
http://rapt.com
Introduction

Rapt Therapeutics, Inc. operates as a clinical stage immunology-based biopharmaceutical company, which engages in the discovery, development, and commercialization of oral small molecule therapies for patients in oncology and inflammatory diseases. The company was founded in 2015 and is headquartered in South San Francisco, CA.

Clinical Trials

8

Active:0
Completed:4

Trial Phases

2 Phases

Phase 1:4
Phase 2:3

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (7 trials with phase data)• Click on a phase to view related trials

Phase 1
4 (57.1%)
Phase 2
3 (42.9%)

Study of RPT193 in Healthy Adult Male Subjects

Phase 1
Completed
Conditions
Healthy Male Subjects
Interventions
Drug: 14C RPT193
First Posted Date
2023-10-18
Last Posted Date
2023-11-29
Lead Sponsor
RAPT Therapeutics, Inc.
Target Recruit Count
7
Registration Number
NCT06087978
Locations
🇺🇸

Celerion, Lincoln, Nebraska, United States

Phase 2 Study to Evaluate RPT193 in Adults With Moderate to Severe T2-high Asthma

Phase 2
Terminated
Conditions
Asthma
Interventions
Other: Placebo
First Posted Date
2023-07-07
Last Posted Date
2024-07-22
Lead Sponsor
RAPT Therapeutics, Inc.
Target Recruit Count
38
Registration Number
NCT05935332
Locations
🇺🇸

Allergy and Asthma Associates of Santa Clara Valley Research Center, San Jose, California, United States

🇺🇸

Bensch Clinical Research LLC, Stockton, California, United States

🇺🇸

Allianz Research Institute, Westminster, California, United States

and more 26 locations

An Efficacy and Safety Study of RPT193 in Adults With Atopic Dermatitis

Phase 2
Terminated
Conditions
Atopic Dermatitis
Interventions
Other: Placebo
First Posted Date
2022-06-01
Last Posted Date
2024-06-14
Lead Sponsor
RAPT Therapeutics, Inc.
Target Recruit Count
229
Registration Number
NCT05399368
Locations
🇺🇸

Cahaba Dermatology and Skin Health Center, Birmingham, Alabama, United States

🇺🇸

Perseverance Research Center, Scottsdale, Arizona, United States

🇺🇸

Arkansas Research Trials, LLC, North Little Rock, Arkansas, United States

and more 56 locations

FLX475 in Combination With Ipilimumab in Advanced Melanoma

Phase 2
Terminated
Conditions
Advanced Melanoma
Interventions
First Posted Date
2021-05-20
Last Posted Date
2023-12-05
Lead Sponsor
RAPT Therapeutics, Inc.
Target Recruit Count
6
Registration Number
NCT04894994
Locations
🇺🇸

University of California, Los Angeles, Los Angeles, California, United States

🇺🇸

Moffitt Cancer Center, Tampa, Florida, United States

🇺🇸

Washington University School of Medicine St. Louis, Saint Louis, Missouri, United States

and more 1 locations

A First-in-Human Study of RPT193 in Healthy Volunteers and Patients With Atopic Dermatitis

Phase 1
Completed
Conditions
Atopic Dermatitis
Interventions
Drug: Placebo
First Posted Date
2020-02-17
Last Posted Date
2021-09-30
Lead Sponsor
RAPT Therapeutics, Inc.
Target Recruit Count
103
Registration Number
NCT04271514
Locations
🇺🇸

Pinnacle Research Group, LLC, Anniston, Alabama, United States

🇺🇸

Perseverance Research Center LLC, Scottsdale, Arizona, United States

🇺🇸

University Clinical Trials, Inc, San Diego, California, United States

and more 11 locations
  • Prev
  • 1
  • 2
  • Next

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.